Molecular Diagnostic Solution Aids in Early Detection of Hepatitis

To tackle this issue, Tianlong Science and Technology (Shaanxi, China), an innovative high-tech company specializing in molecular diagnostic products, has joined forces with public hospitals in northern Thailand. The partnership aims to provide detection for hepatitis C (HCV) and hepatitis B (HBV), facilitating early diagnosis and treatment. Tianlong's detection solution for HCV and HBV can aid in curbing the transmission of the diseases through early diagnosis and appropriate treatment.

Since October 2022, public hospitals in Thailand have successfully implemented Tianlong's HCV and HBV detection solution. The reagents developed by Tianlong for HCV and HBV detection, compatible with its PANA9600S nucleic acid extractor and Gentier 96 PCR system, enable rapid testing with high sensitivity, thereby gaining traction among high-end users. Tianlong has established a 7-year agreement with local Thai hospitals, which plan to progressively adopt its HCV and HBV detection solution. This move has paved the way for Tianlong to penetrate the Thai market and allowed it to strengthen its engagement with local high-end users.

Tianlong is determined to widen its footprint in Thailand, closely collaborating with local partners to deliver top-notch solutions and services for its customers. The company also plans to introduce its STIs kits in Thailand shortly, aiming to curb the spread of sexually transmitted infections (STIs). Tianlong anticipates that its molecular diagnostic solutions for hepatitis and other diseases will gain increasing acceptance in the local market, contributing to the health and well-being of the people in Thailand.

"Tianlong can give timely responses both online and offline when we need technical support. We have great confidence in Tianlong's products, and we would welcome more cooperation in the future," said a local hospital representative in Thailand.

Related Links:
Tianlong Science and Technology